TDP-43 upregulates lipid metabolism modulator ABHD2 to suppress apoptosis in hepatocellular carcinoma

Bo-wen Liu1,2,3✉, Xiang-yun Wang1,2, Jin-ling Cao1,2, Lu-lu Chen1, Yi-lei Wang1, Bing-qian Zhao1, Jia Zhou1 & Zhi-fa Shen1,3✉

TAR DNA-Binding Protein 43 (TDP-43) has been well studied in neurodegenerative diseases, but its potential role in malignance is still unclear. Here, we demonstrate that TDP-43 contributes to the suppression of apoptosis by facilitating lipid metabolism in hepatocellular carcinoma (HCC). In HCC cells, TDP-43 is able to suppress apoptosis while deletion of it markedly induces apoptosis. RNA-sequencing identifies the lipid metabolism gene abhydrolase domain containing 2 (ABHD2) as the target gene of TDP-43. Tissue microarray analysis shows the positive correlation of TDP-43 and ABHD2 in HCC. Mechanistically, TDP-43 binds with the UG-rich sequence1 of ABHD2 3'UTR to enhance the mRNA stability of ABHD2, thereby upregulating ABHD2. Afterwards, TDP-43 promotes the production of free fatty acid and fatty acid oxidation-originated reactive oxygen species (ROS) in an ABHD2-dependent manner, so as to suppress apoptosis of HCC. Our findings provide insights into the mechanism of HCC progression and reveal TDP-43/ABHD2 as potential targets for the precise treatment of HCC.
Hepatocellular carcinoma (HCC), one of the common malignant tumors around the world, has seriously endangered human life and health for many years. The pathogenesis of HCC is complicated, it involves a variety of processes, such as chronic inflammation, liver fibrosis and oncogene dysregulation. The dysregulation of oncogene expression always induces the disorder of the physiological state of cell, which results in excessive proliferation and suppressive apoptosis, accelerating the malignant progression of HCC. Therefore, clarifying the mechanism of initiation and development is crucial for the targeted therapy in HCC.

Transactivation (TAR) DNA-binding protein (TARDBP), also known as TDP-43, was originally identified as a DNA-binding protein capable of regulating human immunodeficiency virus 1 gene expression. Later studies found that TDP-43, encoded by the tardbp gene, is a highly conserved DNA/RNA-binding protein. In the nucleus, TDP-43 can bind to RNA and play an important role in mRNA transcription, splicing, nuclear transport and stability. In the cytoplasm, TDP-43 forms RNP ribonucleoprotein granules that regulate mRNA transport and promote the production of non-coding RNAs such as miRNA. TDP-43 has been focused because of its vital role in neurodegenerative diseases, such as amyotrophic lateral sclerosis and Alzheimer’s disease. Recently, it has been discovered that TDP-43 is closely correlated with the progression of malignant tumors. Studies have shown that TDP-43 is dysregulated in breast cancer, lung cancer, melanoma and other malignant tumors. In breast tumor, TDP-43 can interact with serine and arginine rich splicing factor 3 to modulate the selective splicing of downstream targets PAPR3 and NUMB mRNA, thereby promoting tumor proliferation and metastasis. In lung cancer cells, TDP-43 enhances the mRNA stability of Fasl by interacting with Fasl mRNA, thereby mediating apoptosis and finally inhibiting the progression of lung cancer.

Notably, a previous study shows that TDP-43 elevates the expression of the platelet isoform of phosphofructokinase, a rate-limiting enzyme of glycolysis, to promote cell growth in HCC. This evidence indicates the potential role of TDP-43 in modulating cell metabolism in HCC. Abnormal metabolism is a common hallmark of cancer cells; especially glucose metabolism and lipid metabolism, cancer cells often reprogram these metabolic pathways to meet the energy needs of overgrowth and to resist apoptosis. Liver is an important place for lipid metabolism, and plays a vital role in the absorption, synthesis, decomposition, and transport of lipids. Lipid metabolism disorder usually appears during the occurrence and development of HCC. However, whether TDP-43 has an effect on lipid metabolism in the progression of HCC and the underlying mechanism are still unknown.

In the present study, we uncover that the expression of TDP-43 is negatively related to the overall survival and relapse-free survival of HCC. TDP-43 suppresses the cell apoptosis of HCC through the lipid metabolism-related gene ABHD2. Molecular mechanism investigation reveals that TDP-43 can bind to the 3’UTR of ABHD2 mRNA and enhance the stability of ABHD2 mRNA, thereby upregulating the expression of ABHD2. TDP-43 was able to promote the production of free fatty acid (FFA) and fatty acid oxidation-originated reactive oxygen species (ROS) in an ABHD2-dependent manner, thereby promoting proliferation and inhibiting apoptosis in HCC cells. Our study provides a potential target for the precise treatment of HCC.

**Results**

**TDP-43 inhibits apoptosis and promotes proliferation in HCC cells.** Firstly, we detected the expression levels of TDP-43 in different HCC cell lines by qRT-PCR and Western blot assays. The results in these cell lines showed that the expression of TDP-43 was weakest in Huh-7 cell line while abundantly in SMMC-7721 and MHCC97H cell lines (Supplementary Fig. 1a, b). Accordingly, we selected Huh-7 cells to overexpress TDP-43 and selected SMMC-7721 and MHCC97H cells to knock down TDP-43 in subsequent experiments. To explore the potential role of TDP-43 in HCC progression, we tested the effect of TDP-43 on cell proliferation by colony formation assay. Two different si-TDP-43 (termed as si-TDP-43#1 and si-TDP-43#2) were transiently transfected into SMMC-7721 and MHCC97H cells to specifically silence TDP-43 expression. The results showed that silence of TDP-43 obviously weakened the formation of colony in SMMC-7721 and MHCC97H cells (Fig. 1a, c). However, overexpression of TDP-43 in Huh-7 cells promoted the formation of colony (Fig. 1b, c). Then, we evaluated the effect of TDP-43 on apoptosis by Annexin V-FITC/PI double staining method. Silence of TDP-43 induced apoptosis in MHCC97H and SMMC-7721 cells, while TDP-43 overexpression efficiently suppressed apoptosis in Huh-7 cells (Fig. 1d–g). Next, we used MHCC97H cells to establish a TDP-43 stable-knockdown cell line (MHCC97H-KD-TDP-43) and its control cell line (MHCC97H-Control), and applied them in the subsequent studies. The expression levels of proliferation- and apoptosis-associated markers were evaluated by qRT-PCR and Western blot assay. The results displayed that TDP-43 upregulated the antiapoptotic gene Bcl-2 and proliferation marker Ki67. Meanwhile, TDP-43 downregulated the pro-apoptotic genes p53 and Bax (Fig. 1h, i, Supplementary Fig. 1c–e). Caspase3 is activated to form cleaved-caspase3 (C-caspase3), which is the vital terminal cleavage enzyme in apoptotic processes. TDP-43 could negatively modulate the protein level of C-caspase3 (Fig. 1i). These findings demonstrate that TDP-43 prevents apoptosis and facilitates proliferation in HCC cells.

**TDP-43 accelerates growth and inhibits apoptosis in liver tumor.** In order to further verify the effect of TDP-43 on cell apoptosis and proliferation in HCC, we used MHCC97H-KD-TDP-43 and MHCC97H-Control cells to conduct subcutaneous tumorigenesis experiments in nude mice. The results revealed that the weight and volume of tumors in nude mice were markedly reduced when TDP-43 was silenced (Fig. 2a–c). No difference was observed in the body weights of mice among the two groups, suggesting that the mice remained healthy upon TDP-43 knockdown (Fig. 2d). Subsequently, we evaluated the expressions of Ki67, C-caspase3, p53 and Bcl-2 in tumor tissues by immunohistochemistry (IHC) staining. IHC data uncovered that knockdown of TDP-43 depressed the expression of Ki67 and Bcl-2; Conversely, the expression levels of C-caspase3 and p53 were increased following by TDP-43 knockdown (Fig. 2e, f). These data were in accordance with the aforesaid data in vitro, further indicating the role of TDP-43 on cell apoptosis and proliferation. In addition, we used an online resource to analyze the association between TDP-43 and the prognosis of HCC patients. The results revealed that the higher the expression level of TDP-43, the shorter the overall survival and relapse-free survival (Fig. 2g, h). Meanwhile, analysis of GSE36376 indicated that the expression level of TDP-43 in HCC tissues was substantially higher than that in adjacent non-tumor tissues (Fig. 2i). Therefore, TDP-43 is strongly associated with the poor prognosis of HCC.

**Lipid metabolism-related gene ABHD2 is identified as a target of TDP-43.** To identify the downstream target genes of TDP-43, we performed high-throughput transcriptome sequencing (RNA-seq) and obtained the transcriptome expression profiles of MHCC97H-KD-TDP-43 cells and control cells. After knocking
down TDP-43, the expressions of 1392 genes were increased and 1418 genes were decreased (Supplementary Fig. 2). The differentially expressed genes were displayed by a volcano plot and a hierarchical clustering heatmap (TOP100 of down-regulated genes) (Fig. 3a, b). GSEA analysis revealed that apoptosis was strongly responsive to the change in TDP-43 expression (Fig. 3c), suggesting that TDP-43 is closely related to apoptosis. This was consistent with our previous experimental results (Figs. 1 and 2).

KEGG pathway enrichment analysis was performed on the down-regulated genes, and the results showed that these genes might be more involved in metabolic pathways (Fig. 3d), especially in lipid metabolism pathways (Fig. 3e). To further confirm whether TDP-43 was related to metabolism, we screened all metabolism-related genes in down-regulated genes (TOP50) for expression
Fig. 1 TDP-43 inhibits apoptosis and promotes proliferation in HCC cells. Colony photographs (a, b) and colony formation efficiency (c) after transiently transfected with the displayed siRNAs or plasmids in SMMC-7721, MHCC97H and Huh-7 cells. Scale bar: 2 mm. Flow cytometry analysis of apoptosis in SMMC-7721 (d) or MHCC97H (e) cells after transient transfection with the displayed siRNAs for 48 h and the statistical graphs (including early, late and total apoptosis rates) (f). Flow cytometry analysis of apoptosis in Huh-7 cells after transient transfection with the included plasmids for 48 h (left). The right panel is the statistical graphs (including early, late and total apoptosis rates). h qRT-PCR analysis for the mRNA levels of TDP-43, Bcl-2, Bax and p53. SMMC-7721 cells were transiently transfected with si-Control or si-TDP-43s for 48 h. The data was normalized to the mRNA level of GAPDH. i Western blot analysis for the protein level of Bax, C-caspase3, p53, Bcl-2, Ki67 and TDP-43. The SMMC-7721 and Huh-7 cells were transiently transfected with the displayed siRNAs or plasmids. MHCC97H-KD-TDP-43 and MHCC97H-Control cells were directly used to perform Western blot analysis. The values in the graphs represent the mean of three biologically independent experiments. Error bars represent ± s. d. *P < 0.05, **P < 0.01, ***P < 0.001 by two-tailed Student’s t-test.

verification. Interestingly, compared with other metabolism-related genes, the lipid metabolism-related gene, abhydrolase domain containing 2 (ABHD2) was the most considerably downregulated after TDP-43 knockdown (Fig. 3f). This evidence was consistent with the analysis of the metabolic pathway in Fig. 3e. Thus, we get the conclusion that the lipid metabolism-related gene ABHD2 is identified as a downstream target of TDP-43.

TDP-43 is positively related to ABHD2 and increases ABHD2 expression in HCC. Next, we performed qRT-PCR and Western blot assay in different HCC cell lines to confirm the effect of TDP-43 on ABHD2 expression. Silence of TDP-43 efficiently decreased the expression of ABHD2, while TDP-43 overexpression obviously increased ABHD2 (Fig. 4a-d and Supplementary Fig. 3a, b). Meanwhile, the expression levels of ABHD2 in mice tumor tissues were determined by IHC staining assay. We found that TDP-43 deficiency could reduce the expression of ABHD2 in tumor tissues (Fig. 4e). Moreover, the gene correlation analysis from the online database GEPIA showed that the expression of TDP-43 and ABHD2 in HCC tissues (Fig. 4f, g). To further verify the correlation between the expression of TDP-43 and ABHD2 in HCC tissues, we performed IHC staining on two consecutive sections of HCC tissue microarray. There were 32 cases of HCC tissues and paired non-tumor tissues in the tissue microarray. The result manifested that TDP-43 was positively related to ABHD2 in HCC tissues (Fig. 4h, i, and Supplementary Fig. 3c, Pearson’s chi-square independent test, $\chi^2 = 61.41, P < 0.0001$).

TDP-43 upregulates ABHD2 through enhancing the mRNA stability of ABHD2. Next, we aimed to elucidate the upregulation mechanism of ABHD2 mediated by TDP-43. TDP-43 is an RNA-binding protein, which can regulate the splicing, transport and stability of RNA. Therefore, we wondered whether TDP-43 exerted a regulatory role by binding to ABHD2 mRNA. The RNA immunoprecipitation (RIP) assay in MHCC97H cells showed that TDP-43 could indeed bind to ABHD2 mRNA (Fig. 5a). To further explore whether TDP-43 regulates ABHD2 at the transcriptional or post-transcriptional level, we performed mRNA stability assays in different HCC cell lines. qRT-PCR results indicated that knockdown of TDP-43 could still downregulate the mRNA level of ABHD2 after time-dependently treated with transcription inhibitor Actinomycin-D (ActD) (Fig. 5b, c). This evidence uncovered the promotion of TDP-43 on ABHD2 mRNA stability.

Studies have shown that TDP-43 has a high affinity for UG-rich sequences, which can bind to them and regulate the maturation of pre-mRNA. After sequence analysis, we found there were two UG-rich sequences in the 3′UTR of ABHD2 mRNA. Therefore, we cloned the 3′UTR of ABHD2 mRNA and constructed it into a luciferase vector (pGL3-Control). The data showed that overexpression of TDP-43 could upregulate the luciferase activity of ABHD2 3′UTR, while TDP-43 silencing markedly inhibited the luciferase activity (Fig. 5d, e). Then, we separately deleted the two UG rich sequences in ABHD2 3′UTR (termed as Del-1 and Del-2, respectively: the former construction of ABHD2 3′UTR termed as WT) (Fig. 5f), and detected the activities of luciferase reporter. After overexpression of TDP-43, the luciferase activities of WT and Del-2 were increased; similarly, the luciferase activities of WT and Del-2 were decreased upon TDP-43 deletion (Fig. 5g, h). However, the luciferase activity of Del-1 did not change obviously no matter TDP-43 was knocked down or overexpressed (Fig. 5g, h). These above results indicate that TDP-43 binds to the UG-rich sequence 1 of ABHD2 3′UTR, enhances the stability of ABHD2 mRNA, and then upregulates its expression.

Lipid metabolism modulator ABHD2 contributes to the malignant behaviors of HCC. ABHD2, a member of α/β-hydrolase domain (ABHD) family, has the lipase serine nucleophilic motif GXXSG and can participate in lipid metabolism by exerting triacylglycerol lipase activity. Under the action of triacylglycerol lipase, triacylglycerols (TG) are hydrolyzed to produce fatty acid. Therefore, we examined the effects of ABHD2 on intracellular TG levels. The data displayed that deletion of ABHD2 obviously induced the accumulation of TG in SMMC-7721 and MHCC97H cells (Supplementary Fig. 4a, b). Meanwhile, the content of free fatty acid (FFA) was efficiently decreased after ABHD2 knockdown (Fig. 6a), indicating that ABHD2 can indeed serve as triacylglycerol lipase to promote the generation of fatty acid.

In the liver, mitochondrial β-oxidation is one of the major metabolic fates of FFAs, which will increase the production of ROS. Studies have shown that ROS is critical for cell survival, and small increases in ROS levels can lead to the activation of some proto-oncogenic pathways and facilitate cancer development. We examined the cellular ROS level and found that ABHD2 could indeed induce the generation of ROS (Fig. 6b, c). Thus, we speculated that ABHD2 might affect the development of HCC through the ROS produced by FFA metabolism. Expectedly, the silence of ABHD2 remarkably increased the apoptotic rate in SMMC-7721 and MHCC97H cells (Fig. 6d–f). The result of western blot further showed that after ABHD2 knocking down, the expression levels of p53, C-caspase3 and Bax were elevated, while the expression level of antiapoptotic gene Bcl-2 was reduced (Fig. 6g and Supplementary Fig. 4c). In addition, CCK-8 and colony formation assay showed that ABHD2 deficiency also resulted in the inhibition of cell proliferation (Supplementary Fig. 4d, e). Then, we aimed to investigate the role of ROS in ABHD2-suppressed apoptosis. We carried out flow cytometry, qRT-PCR, and Western blot assays in ABHD2-overexpressed Huh-7 cells upon the treatment of ROS scavenger N-Acetyl-L-cysteine (NAC). The results showed that NAC treatment could alleviate the inhibition of apoptosis induced by ABHD2 overexpression (Supplementary Fig. 5), suggesting that ABHD2 inhibits apoptosis in an ROS-dependent manner.
TDP-43 facilitates lipid metabolism via ABHD2 to suppress apoptosis in vitro. Next, we wondered whether TDP-43 could modulate lipid metabolism by ABHD2 to suppress apoptosis. First, we performed TG assays in SMMC-7721 and MHCC97H cells. Notably, TDP-43 knockdown induced the accumulation of TG while elevation of ABHD2 could alleviate this phenomenon (Supplementary Fig. 6a). Furthermore, when TDP-43 was silenced, the FFA content was decreased (Fig. 7a). However, overexpression of ABHD2 could efficiently relieve the decrease of FFA induced by TDP-43 deficiency (Fig. 7a). Determination of ROS level also manifested the rescue effect of ABHD2 on TDP-43 deletion-induced decrease of ROS (Fig. 7b, c). Then, we aimed to confirm the role of ABHD2 in TDP-43-regulated cell apoptosis. Expectedly, ABHD2 markedly suppressed the apoptosis induced by the lack of TDP-43 (Fig. 7d, e). QRT-PCR and western blot further showed that ABHD2 disrupted the upregulation of p53.
and C-caspase3 evoked by TDP-43 knockdown; TDP-43 deletion induced-downregulation of Bcl-2 and Ki67 was also improved by ABHD2 (Fig. 7f, g and Supplementary Fig. 6b). In addition, CCK-8 data uncovered that elevation of ABHD2 could improve the decline of cell proliferation induced by TDP-43 knockdown (Supplementary Fig. 6c). Considering that the anti-apoptotic effect of TDP-43 was mediated through ABHD2-associated lipid metabolism, we next evaluated the role of the metabolite FFA in TDP-43-inhibited apoptosis. We performed rescue experiments by FFA in SMMC-7721 cells with knockdown of TDP-43. Flow cytometry, qRT-PCR and Western blot assays showed that FFA treatment effectively reversed the apoptosis caused by TDP-43
TDP-43 facilitates lipid metabolism via ABHD2 to suppress apoptosis in vivo. Next, we constructed stable overexpression of ABHD2 cell lines based on MHCC97H-KD-TDP-43 and MHCC97H-Control cells. The above cells (MHCC97H-Control + vector, MHCC97H-KD-TDP-43 + vector and MHCC97H-KD-TDP-43 + ABHD2) were collected for subcutaneous tumor implantation in nude mice. After 42 days, the subcutaneous tumors of three groups were collected and the tumor weight was detected. The results showed that overexpression of ABHD2 effectively alleviated the inhibition of tumor growth caused by TDP-43 deletion (Fig. 8a–c). Examination of FFA content in mice tumors also manifested the same result: TDP-43 deletion induced-reduction of FFA could be rescued by ABHD2 overexpression (Fig. 8d). Then, the protein abundances of TDP-43, ABHD2, Ki67, C-caspase3, p53 and Bcl-2 in tumor tissues were detected by IHC staining. We observed that deletion of TDP-43 caused the downregulation of Ki67 and Bcl-2, and the upregulation of p53 and C-caspase3 in mice tumors in contrast to the control group (Fig. 8e, f). However, ABHD2 overexpression appreciably relieved the above phenomenon (Fig. 8e, f). Taken together, these findings disclose that TDP-43 can facilitate lipid metabolism by upregulating ABHD2, to inhibit apoptosis in HCC cells.

Discussion

Over the years, with the development of medicine, we have made considerable progress in the diagnosis and treatment of HCC; however, statistics have showed that almost 70% of patients recur within 5 years after operation. Therefore, the exploration of strategies and targets for the treatment of HCC has never stopped. The poor prognosis of HCC is mainly related to the delay of diagnosis. Study of biomarkers may provide more instructive information for the individualized diagnosis and/or prognosis of HCC. The role of TDP-43 in neurological diseases has been well studied, but its potential function in malignant tumors still needs to be explored. In our study, survival analysis manifested that the higher the expression level of TDP-43, the shorter the survival rate of HCC patients. Moreover, TDP-43 has been proved to inhibit apoptosis and promote proliferation in HCC cells, thus accelerating the malignant development of HCC. Our discovery is expected to provide a biomarker for the treatment of HCC, so as to be applied to the diagnosis and prognosis of patients.

To elucidate the mechanism of TDP-43 promoting HCC, we implemented high-throughput sequencing and found that TDP-43 was indeed closely related to the apoptotic pathway. Interestingly, KEGG analysis showed that metabolic pathways strongly responded to the changes in TDP-43 expression. Therefore, we suspected that TDP-43 was likely to suppress the apoptosis of HCC by affecting metabolic pathways. The further classification analysis of KEGG pathway discovered the close association between lipid metabolism and TDP-43. Lipids are critical to the cellular life as molecules for energy storage, membrane structure and signal transduction. So, we supposed whether TDP-43 modulated lipid metabolism-related gene in HCC. In order to confirm our speculation, we detected the expression of all metabolism-related genes among the differential downregulated genes (Top50) and observed that the lipid metabolism-related gene ABHD2 was most dramatically downregulated after TDP-43 silencing. ABHD2, as a member of the mammalian ABHD family, is a triacylglycerol lipase with ester hydrolysis ability. Conserved structural motifs shared by the members of ABHD family primarily play a role in lipid synthesis and degradation. In recent years, the ABHD family has emerged as a potential regulator of signal transduction and lipid metabolism. The above findings led us to investigate whether TDP-43 could modulate lipid metabolism via ABHD2. TG and FFA content examination displayed that TDP-43 enhanced the TG-originated production of FFA in an ABHD2-dependent manner. Fatty acid oxidation (FAO)-originated ROS maybe a major source of ROS and plays a crucial role in oxidative stress during FFA overload in the liver. By detecting intracellular ROS levels, we discovered TDP-43 was able to elevate the content of ROS through ABHD2. The production of ROS could activate multiple oncogenic signaling pathways and furthermore contribute to the pathogenesis of multiple diseases, including cancers. Expectedly, we found that ABHD2 could robustly attenuate the promotion of apoptosis induced by TDP-43 deletion. Moreover, FFA treatment also efficiently alleviate TDP-43 deficiency-caused apoptosis. These evidences revealed that with the help of ABHD2, TDP-43 regulated lipid metabolism, which had an impressive effect on tumor cell apoptosis.

Notably, few studies have addressed the role of ABHD2 in malignant tumors. It is reported that the expressions of ABHD2 in breast cancer and melanoma are obviously higher than those in normal tissues, but whether it has molecular functions in these two cancers is still unknown. The Obinata team has reported that ABHD2 is an androgen-responsive gene, and it can promote the growth and migration of prostate cancer. However, in HCC, the expression and underlying function of ABHD2 remains to be elucidated. In this study, we first put forward that ABHD2 played a crucial role in inhibiting apoptosis and promoting proliferation in HCC. A study in 2009 found that increased apoptosis could be observed in ABHD2 gene deficient mice, which was consistent with our findings. In conclusion, our data suggested that ABHD2 had significance in tumor development and was expected to be a potential target for the precise treatment of HCC.

In the study of the mechanism of TDP-43 regulating ABHD2, we confirmed that TDP-43 bind to the site1 (UG-rich sequence) to enhance the mRNA stability of ABHD2, thus upregulating ABHD2. Interestingly, we also found that ABHD2 had a certain effect on the expression of TDP-43. Western blot and qRT-PCR data displayed that the level of TDP-43 expression was upregulated after ABHD2 overexpression (Fig. 7f, g). Especially in the
Fig. 4 TDP-43 is positively related to ABHD2 and increases ABHD2 expression in HCC. a–c qRT-PCR assay to detect the effect of TDP-43 on ABHD2 expression in HCC cells. The MHCC97H-KD-TDP-43 and MHCC97H-Control cells were used for the assay in (a). The cells (SMMC-7721 and Huh-7) were transiently transfected with the indicated siRNAs or plasmids. The data was normalized to the mRNA level of GAPDH. d Western blot analysis was performed to detect the effect of TDP-43 on ABHD2 expression in Huh-7 and SMMC-7721 cells. The cells were transiently transfected with the indicated siRNAs or plasmids for 48 h. e IHC staining of ABHD2 in the xenograft tumors derived from MHCC97H-KD-TDP-43 and MHCC97H-Control cells. The right panel is the quantitative analysis. Scale bar: 50 μm. Expression correlation analysis of TDP-43 and ABHD2 genes in Tumor (f), and Tumor and normal (g) in the GEPIA database (http://gepia.cancer-pku.cn/detail.php). h Heat map of the expression levels of TDP-43 and ABHD2 in HCC tissue microarray. Numbers 0, 1, 2 or 3 represent negative, weak, moderate or strong staining, respectively. i Statistical analysis of the association between TDP-43 and ABHD2 expression levels in the abovementioned tissue microarray by Pearson chi-square independent test, χ² = 61.41, P < 0.0001. The values in the graphs represent the mean of three biologically independent experiments. Error bars represent ± s. d. *P < 0.05, **P < 0.01, ***P < 0.001 by two-tailed Student’s t test.
qRT-PCR experiment, ABHD2-induced upregulation of TDP-43 showed noticeable statistical significance. Therefore, we speculated that ABHD2 might be able to reversely regulate the expression of TDP-43. However, whether there was a positive feedback loop between TDP-43 and ABHD2 to jointly promote the development of HCC or other tumors is still unclear.

In summary, our study discloses a mechanism for TDP-43-promoted HCC progression (Fig. 9). As an RNA-binding protein, TDP-43 can bind to the mRNA 3′ UTR of lipid metabolism-related gene ABHD2, enhance the stability of ABHD2 mRNA, and then upregulate ABHD2. Elevated-ABHD2 catalyzes the metabolic process of TG to FFAs, thus promoting the β-oxidation pathway and increasing the production of ROS, finally resulting in the suppression of apoptosis and facilitation of proliferation in HCC. Our study provides a theoretical basis for elucidating the role of RNA-binding proteins in the promotion of malignance. Meanwhile, TDP-43/ABHD2 can be used as potential target, which has important application value in the precise treatment of HCC.

Methods
Plasmid construction and small interference RNA (siRNA). Using the mRNA extracted from SMMC-7721 cells as the template, the coding region sequence (CDS) of TDP-43 was amplified by RT-PCR. During amplification, the enzyme...
digestion sites were introduced. The PCR products and vector pEGFP-C2 were double digested, respectively. Then, the PCR products were connected with pEGFP-C2 by T4 DNA ligase. Finally, the recombinant plasmid pEGFP-TDP-43 was used for exogenous overexpression of TDP-43. The pCMV3-ABHD2 expression plasmid was purchased from Sino Biological (China, HG14770-CF) and was used for ABHD2 overexpression. The 3’UTR of ABHD2 was amplified by PCR using specific primers and inserted into the pGL3-Control vector to generate the pGL3-ABHD2-3’UTR (WT). Then, two sites rich in UG sequence were separately deleted to construct two different ABHD2 3’UTR mutants (Del-1 and Del-2). All siRNAs used in this study were generated by RiboBio (Guangzhou, China), and the sequences of siRNAs were listed in the Supplementary Table 1. The primer sequences used in ABHD2 3’UTR construction were shown in Supplementary Table 3.

**Western blot assay.** Total proteins were extracted by RIPA buffer (Beyotime, China) containing 1nmol/L PMSF (Beyotime). The proteins were resolved by SDS-PAGE and then transferred on a polyvinylidene fluoride membrane (GE Healthcare Life Sciences, USA). After incubation with 5% skimmed milk at room temperature for 2 h, the blot was hybridized with the primary antibody at 4°C.
Fig. 7 TDP-43 facilitates lipid metabolism via ABHD2 to suppress apoptosis in vitro. a Analysis of FFA levels in SMMC-7721 (left) and MHCC97H (right) cells. The cells were transiently transfected with si-Control/si-TDP-43#2 and pCMV3 (vector)/pCMV3-ABHD2 to silence TDP-43 or overexpress ABHD2. Quantitative analysis (b) and fluorescence images (c) of reactive oxygen species (ROS) in SMMC-7721 and MHCC97H cells after transient transfection with the displayed siRNAs or plasmids. Scale bar: 200 µm. d Flow cytometry analysis of apoptosis in SMMC-7721 (upper panel) and MHCC97H (lower panel) cells upon TDP-43 deletion along with or without ABHD2 overexpression. e Quantitative analysis of apoptotic rate in (d). f qRT-PCR assay for the mRNA levels of TDP-43, ABHD2 and Bcl-2 in SMMC-7721 cells upon TDP-43 deletion along with or without ABHD2 overexpression. The data was normalized to the mRNA level of GAPDH. g Western blot analysis of protein levels of ABHD2, p53, Bcl-2, C-caspase3, Ki67, and TDP-43 in SMMC-7721 and MHCC97H cells. Group number 1, 2, and 3 separately represents the three groups shown in (f). The cells were transiently transfected with the displayed siRNAs or plasmids. The values in the graphs represent the mean of three biologically independent experiments. Error bars represent ± s. d. *P < 0.05, **P < 0.01, ***P < 0.001 by two-tailed Student’s t test.
overnight. After washing by TBST three times, the blot was incubated with the secondary antibody (Beyotime, A0208, A0216, dilution: 1:1000) at room temperature for 1 h. After adding the enhanced chemiluminescence (NCM Biotech, China), the immunoblots were obtained using Azure600 (azure biosystems, USA).

The primary antibodies used in this study were GAPDH (Abcam, UK, ab181602, dilution: 1:5000), TDP-43 (Abcam, ab190963, dilution: 1:2000), ABHD2 (absin, China, abs140798, dilution: 1:1000), Cleaved-caspase3 (#9664, dilution: 1:2000), p53 (proteintech, USA, 10442-1-AP, dilution: 1:5000), Bax (Cell Signaling, #5023, dilution: 1:1000), Bcl-2 (Abcam, ab182858, dilution: 1:2000), Ki67 (Abcam, ab16667, dilution: 1:1000).

Flow cytometry assay. In total, 1×10^5 cells were plated into 6-well plates and were harvested after transfection for 48 h. After washing with precooled PBS, the binding buffer was added to resuspend cells. Subsequently, dye the cells with 5 μl Annexin V-FITC and 5 μl propidium (KeyGen Biotech, China). Within 1 h, the apoptotic cells were detected by flow cytometry. Three replicates were set in each group.

Determination of FFA content. To evaluate intracellular lipid metabolism, cells were seeded on a 6-well plate and collected after transfection for 48 h. According to the manufacturer’s operating instructions, the FFA levels were determined using a
Free Fatty Acid Quantification Kit (CoMIN, China). For tumor metabolism analysis, the mice tumor tissues need to be ground in an ice bath naturally cooled before treating with 3% H2O2 for 10 min. Sections were blocked in 5% normal goat serum for 30 min at room temperature, and then incubated overnight with indicated primary antibody at 4°C. After three washes with PBS, the slides were hybridized with the secondary antibody (Servicebio, GB23303, dilution: 1:200) for 50 min at room temperature. Finally, diaminobenzidine (DAB) (service) was used for staining analysis. Dehydrate the slides and seal with neutral gum (Solarbio, China). Image J software was used for staining analysis.

RNA immunoprecipitation (RIP). The RIP assay was conducted to examine the interaction of TDP-43 and ABHD2 mRNA. Briefly, HCC cells were gathered by centrifugation and then lysed with RIP lysis buffer containing RNAase inhibitor. The protein A + G agarose beads (Millipore, USA) were re-suspended and incubated with TDP-43 antibody or control IgG for 1 h. Next, the cell lysate was incubated with the above-prepared agarose beads at 4°C overnight. After repeated washing with NT-2 buffer for 6–8 times, added protease K buffer into agarose beads and water bath at 55°C for 30 min to remove protein. Finally, NT-2 buffer was added and immunoprecipitated RNA was extracted with Trizol reagent for qRT-PCR analysis.

Statistical analysis. All replicates displayed in this paper are biological replicates; technical replicates (usually three) were performed and used to generate the means for each biological replicate. The sample sizes and number of replicates were indicated in the figure legends. Graph pad prism 8.0 (San Diego, USA) was used for statistical analysis. The statistical significance was evaluated by comparing the mean of three biologically independent experiments using a 2-tailed student’s t-test. Error bars represent ± s.d. A value of P < 0.05 was considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001. The correlations between TDP-43 expression with the relapse-free survival and overall survival were separately analyzed via the online resource Kaplan-Meier Plotter (https://kmplot.com/analysis/index.php?cancer=rnaseqp&service=) and GEPIA (http://gepia.cancer-pku.cn/). In the analysis of HCC tissue microarray, the correlation between TDP-43 and ABHD2 expression was determined according to Pearson’s chi-square independent test.

Data availability. The source data underlying the graphs presented in the main figures are shown as Supplementary data 1. Uncropped blots can be found in Supplementary Figs. 7–10. RNA-seq data are available in SRA database of NCBI as PRJNA855537. Plasmids for TDP-43 expression and ABHD2-3’UTR are deposited at Addgene (Accession numbers 190093, 190094, 190095 and 190096). All other data supporting the findings of the study are available within the paper and Supplementary information. Data relating to Supplementary figures are available from Zhi-fa Shen or Bo-wen Liu upon reasonable request.

Received: 10 February 2022; Accepted: 2 August 2022; Published online: 13 August 2022

References

1. Huang, A., Yang, X. R., Chung, W. Y., Dennison, A. R. & Zhou, J. Targeted therapy for hepatocellular carcinoma. Signal Transduct. Target Ther. 5, 146 (2020).
2. Jia, B., Song, E. L. & El-Serag, H. B. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 156, 477–491.e471 (2019).
3. Kim, E. & Viatour, P. Hepatocellular carcinoma: old friends and new tricks. Exp. Mol. Med. 52, 1898–1907 (2020).
4. Brown, G. Oncogenes, proto-oncogenes, and lineage restriction of cancer stem cells. Int. J. Mol. Sci. 22, 9667 (2021).
5. Chhangani, D., Martin-Pena, A. & Rincon-Limas, D. E. Molecular, functional, and pathological aspects of TDP-43 fragmentation. iScience 24, 102459 (2021).
8. Buratti, E. & Baralle, F. E. Multiple roles of TDP-43 in gene expression.
9. Costessi, L., Porro, F., Iaconcig, A. & Muro, A. F. TDP-43 regulates beta-
10. Protein Cell
14
11. Cohen, T. J., Lee, V. M. & Trojanowski, J. Q. TDP-43 functions and
12. Pope, E. D. 3rd et al. Aberrant lipid metabolism as a therapeutic target in liver
13. Yang, L. T. et al. Restoration of Mal overcomes the defects of apoptosis in lung
14. Ke, H. et al. Loss of TDP43 inhibits progression of triple-negative breast
15. Choudhary, G. S., Al-Harbi, S. & Almasan, A. Caspase-3 activation is a critical
16. Chen, Z., Tian, R., She, Z., Cai, J. & Li, H. Role of oxidative stress in the
17. Patel, N., Yopp, A. C. & Singal, A. G. Diagnostic delays are common among
18. Ke, H. et al. Loss of TDP43 inhibits progression of triple-negative breast
19. Sullivan, L. B. & Chandel, N. S. Mitochondrial reactive oxygen species and cancer. Cancer Metab. 2, 17 (2014).
20. Villanueva, A. et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 140, 1501–1512.e1502 (2011).
21. Patel, N., Yopp, A. C. & Singal, A. G. Diagnostic delays are common among patients with hepatocellular carcinoma. J. Natl Compr. Canc Netw. 13, 543–549 (2015).
22. Huang, C. & Freter, C. Lipid metabolism, apoptosis and cancer therapy. Int. J. Mol. Sci. 16, 924–949 (2015).
23. Lord, C. C., Thomas, G. & Brown, J. M. Mammalian alpha beta hydrolase domain (ABHD) proteins: Lipid metabolizing enzymes at the interface of cell signaling and energy metabolism. Biochim. Biophys. Acta 1831, 792–802 (2013).
24. Chen, Z., Tian, R., She, Z., Cai, J. & Li, H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radics. Biol. Med. 152, 116–140 (2020).
25. Liu, L. et al. The liver as a regulator of fatty acid metabolism. Trends Mol. Biol. 56, 1283–1297 (2009).
26. Talavera, F. D. & Kowaltowski, A. J. Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species scavenging. Free Radics. Biol. Med. 46, 1283–1297 (2009).
27. Koundourou, N. & Poulogiannis, G. Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer. Front Oncol. 8, 160 (2018).
28. Yang, Y. et al. Mitochondria and mitochondrial ROS in cancer: novel targets for anticancer therapy. J. Cell Physiol. 231, 2570–2581 (2016).
29. Park, Y. Y. et al. Tat-activating regulatory DNA-binding protein regulates cation of TDP-43 as an oncogene in melanoma and its pathogenic mechanisms implicated in TDP-43 proteinopathies. Trends Mol. Med. 17, 659–667 (2011).
30. Sullivan, L. B. & Chandel, N. S. Mitochondrial reactive oxygen species and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J. Virol. 69, 3584–3596 (1995).
31. Zeng, Q. et al. Identification of TDP-43 as an oncogene in melanoma and its prognostic value in melanoma pathogenesis, the major project of Zhejiang Provincial Natural Science Foundation (Grant NO. LZ22H160007), and the Natural Science Foundation of Henan Province (Grant NO. 22230402062).
32. Patel, N., Yopp, A. C. & Singal, A. G. Diagnostic delays are common among patients with hepatocellular carcinoma (HCC) as well as immune microenvironment: A review. Cell Prolif. 53, e12772 (2020).
33. M, N. K. et al. Molecular characterization of human ABHD2 as TAG lipase and ester hydrolase.
34. Lord, C. C., Thomas, G. & Brown, J. M. Mammalian alpha beta hydrolase domain (ABHD) proteins: Lipid metabolizing enzymes at the interface of cell signaling and energy metabolism. Biochim. Biophys. Acta 1831, 792–802 (2013).
35. Chen, Z., Tian, R., She, Z., Cai, J. & Li, H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radics. Biol. Med. 152, 116–140 (2020).
36. Tahara, E. B., Navarete, F. D. & Kowaltowski, A. J. Tissue-, substrate-, and site-specific characteristics of mitochondrial reactive oxygen species scavenging. Free Radics. Biol. Med. 46, 1283–1297 (2009).
37. Koundourou, N. & Poulogiannis, G. Phosphoinositide 3-Kinase/Akt Signaling and Redox Metabolism in Cancer. Front Oncol. 8, 160 (2018).
38. Yang, Y. et al. Mitochondria and mitochondrial ROS in cancer: novel targets for anticancer therapy. J. Cell Physiol. 231, 2570–2581 (2016).
39. Richardson, A. L. et al. Chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 9, 121–132 (2006).
40. Finak, G. et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat. Med. 14, 518–527 (2008).
41. Talavera, F. D. et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin. Cancer Res. 11, 7234–7242 (2005).
42. Obinata, D. et al. Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration. Eur. J. Cancer 57, 39–49 (2016).
43. Jin, S. et al. Age-related pulmonary emphysema in mice lacking alpha/beta hydrolase domain containing 2 gene. Biochem. Biophys. Res. Commun. 380, 419–424 (2009).